Literature DB >> 11110047

Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase.

N Bagge1, O Ciofu, L T Skovgaard, N Høiby.   

Abstract

The aim of this study was to examine the development of resistance of biofilm-growing P. aeruginosa during treatment with ceftazidime. Biofilms were established in vitro using a modified Robbins device (MRD) and in vivo in the rat model of chronic lung infection. Three P. aeruginosa strains isolated from the lungs of cystic fibrosis (CF) patients (MICceftazidime-basal/induced beta-lactamase activity: PAO 579= 0.8 mg/l-19/550 milliunits, 19676A=50 mg/l-38/957 milliunits, 17107B=100 mg/l-504/947 milliunits) were studied. After 1 or 2 weeks of continuous or intermittent (4 h/day) administration of ceftazidime to biofilms established in MDR, a statistically significant development of resistance to ceftazidime in PAO 579 or 19676A bacterial populations occurred. When ceftazidime was administered 4 h/day (200 mg/l) for 2 weeks, the frequency of resistant 19676A having MIC>25 mg/l was 4.4 10(-1) compared to 6.0-10(-5) in the control biofilm. The same trend was observed after continuous administration of ceftazidime. MICceftazidime of the more resistant variants was increased 500-fold for PAO 579 and 8-fold for 19676A, and the specific basal beta-lactamase activities from 19 to 1,400 units for PAO 579 and from 38 to 10,000 units for 19676A. Chronic P. aeruginosa lung infection was established with alginate-embedded PAO 579, 19676A or 17107B in 146 Lewis rats which were treated with ceftazidime 4 g/kg intraperitoneally twice a day for 1 week. A statistically significant development of resistance was observed for all three strains. The MICceftazidime of the more resistant variants was increased 15-fold for PAO 579, 8-fold for 19676A, and 4-fold for 17107B, and the specific basal 3-lactamase activity from 19 to 100 units for PAO 579, from 38 to 1,300 units for 19676A, and from 500 to 1,300 units for 17107B. It was shown that, during treatment with ceftazidime, biofilm-growing P. aeruginosa had the capacity to develop resistance due to the production of chromosomal beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110047     DOI: 10.1034/j.1600-0463.2000.d01-102.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  13 in total

1.  Towards "molecular Esperanto" or the Tower of Babel? (the need for harmonization of techniques for genotyping clinical isolates of Pseudomonas aeruginosa isolated from patients with cystic fibrosis).

Authors:  John E Moore; Colin E Goldsmith; J Stuart Elborn; Philip G Murphy; Peter H Gilligan; Séamus Fanning; Graham Hogg
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD.

Authors:  Niels Bagge; Oana Ciofu; Morten Hentzer; Joan I A Campbell; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

4.  Characterization of phenotypic changes in Pseudomonas putida in response to surface-associated growth.

Authors:  K Sauer; A K Camper
Journal:  J Bacteriol       Date:  2001-11       Impact factor: 3.490

5.  Growing Burkholderia pseudomallei in biofilm stimulating conditions significantly induces antimicrobial resistance.

Authors:  Chakrit Sawasdidoln; Suwimol Taweechaisupapong; Rasana W Sermswan; Unchalee Tattawasart; Sumalee Tungpradabkul; Surasakdi Wongratanacheewin
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

6.  A temporal examination of the planktonic and biofilm proteome of whole cell Pseudomonas aeruginosa PAO1 using quantitative mass spectrometry.

Authors:  Amber J Park; Kathleen Murphy; Jonathan R Krieger; Dyanne Brewer; Paul Taylor; Marc Habash; Cezar M Khursigara
Journal:  Mol Cell Proteomics       Date:  2014-02-16       Impact factor: 5.911

7.  High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms.

Authors:  Wang Hengzhuang; Oana Ciofu; Liang Yang; Hong Wu; Zhijun Song; Antonio Oliver; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

8.  Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system.

Authors:  L F Mandsberg; O Ciofu; N Kirkby; L E Christiansen; H E Poulsen; N Høiby
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

9.  Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms.

Authors:  Giorgia Borriello; Erin Werner; Frank Roe; Aana M Kim; Garth D Ehrlich; Philip S Stewart
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 10.  Infection of orthopedic implants with emphasis on bacterial adhesion process and techniques used in studying bacterial-material interactions.

Authors:  Marta Ribeiro; Fernando J Monteiro; Maria P Ferraz
Journal:  Biomatter       Date:  2012 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.